Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Obesity, Type 2 Diabetes Mellitus in Obese
Interventions
K-757 and K-833, Matching placebo to K-757 and K-833
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Newark, Delaware
Conditions
Acute Migraine
Interventions
Elismetrep, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
113
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more
Conditions
Obesity
Interventions
K-757, K-757 and open-label sitagliptin, Matching placebo to K-757, Matching placebo to K-757 and matching placebo to K-833, K-757 and K-833, Matching placebo to K-757, open-label sitagliptin
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Acute Migraine
Interventions
Placebo, K-645 dose level 1, K-645 dose level 2
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
18
States / cities
Oceanside, California • Atlanta, Georgia • Stockbridge, Georgia + 15 more
Conditions
Obesity
Interventions
K-757 120 mg BID and K-833 100 mg BID, K-757 120 mg BID and matching placebo to K-833, Matching placebo to K-757 and matching placebo to K-833
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
San Diego, California • Stockbridge, Georgia • Topeka, Kansas + 19 more
Conditions
Obesity, Type 2 Diabetes Mellitus (T2DM)
Interventions
K-757 and K-833 QD, K-757 and K-833 BID, Matching placebo to K-757 and K-833 QD, Matching placebo to K-757 and K-833 BID
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Conditions
Migraine
Interventions
Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Conditions
Migraine
Interventions
Elismetrep, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
113
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more
Conditions
Migraine
Interventions
Elismetrep, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
72
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 64 more